
Johnson & Johnson’s TREMFYA treatment for active Psoriatic Arthritis (PsA) has returned positive results in its Phase III trial.

Novartis is to present data from four pivotal Phase III trials in two debilitating inflammatory diseases at the American College …

AstraZeneca has launched a new app that helps prostate cancer patients to monitor their PSA levels. It is not the …
Long-acting therapies set to reshape HIV treatment market
MHRA approves Romvimza for tenosynovial giant cell tumour

